Shares of Rosetta Genomics (ROSG), which develops and commercializes microRNA-based molecular diagnostics, advanced in early trading after the company announced the recent publication of data from a study assessing the differences between cancer of unknown primary, or CUP, and metastatic solid tumors of known primary metastases, or KPM, by profiling microRNA expression. According to the company's press release, the study's author, George Pentheroudakis, said, "This research is the first look for microRNA characteristics of CUP tumors. Study results confirmed epidemiologic evidence suggesting that patients with favorable prognosis CUP have a presentation, response to therapy and outcome no different from metastatic tumors of matched primaries." The company's CEO said, "This publication demonstrates the utility of microRNA profiling in understanding the biology of CUP and may have important implications for the prognosis and treatment of CUP patients," adding that the company looks forward to the publication of the full data set. The company offered a link to an abstract of the study, which had an e-publication date of Nov. 4, 2012 ahead of its print publication, according to the post on the site of the U.S. National Library of Medicine and National Institutes of Health. In early morning trading, Rosetta Genomics shares rose $1.02, or 22.05% to $5.62.